Background: Replacement of missing tooth plays an important role in patient’s comfort and self-esteem. Aims and Objectives: The aims of this study were to investigate the most commonly used impression materials and techniques practiced for crowns and bridgework by prosthodontists and general dental practitioners compared to the theoretical methods suggested in the literature and to determine the clinical factors that might influence the decision-making process for the selection of impression materials and techniques. Materials and Methods: Pre-tested and pre-validated structured and closed-ended anonymous questionnaire was shared with general dental practitioners and prosthodontists. Results: Most of the prosthodontists use diagnostic impression compared to general dental practitioners (P<0.01). Full-arch tray was used by general dental practitioners significantly more frequently compared to prosthodontists (P<0.01) for single anterior, single posterior, anterior, and posterior bridge preparations. Alginate hydrocolloid was used by general dental practitioners significantly more than prosthodontists (P<0.05); however, addition silicone and condensation silicone were used by prosthodontists significantly more than general dental practitioners (P<0.05). For the impression technique followed in case of using elastomeric impression materials, the prosthodontists used the two-step putty reline technique with spacer more commonly, while general dental practitioners used the multiple mix technique (P<0.01). For the use of provisional restoration for single tooth crowns and for all the bridges, prosthodontists used provisional restoration in significantly higher proportion as compared to general dental practitioners (P<0.01). Conclusion: According to our study compared to general dental practitioners, practices of the prosthodontists regarding use of fixed partial denture is more in line with the current global trend.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is a frequent cause of end-stage renal disease. Despite improvements in blood pressure and conventional treatment, there seems not any significant impact on the need for renal replacement therapy in these cases. Inhibition of cyclic adenosine monophosphate pathway by tolvaptan was efficient in preclinical/animal studies and in clinical studies involving ADPKD patients; tolvaptan (vasopressin V2 receptor antagonist) has been recently released in the market to delay disease progression. Aims and Objectives: The aim of this study is to evaluate the role of tolvaptan in reduction of total kidney volume (TKV), total renal cyst volume, and decrease of progression of renal impairment and restoration of kidney function. Materials and Methods: We have screened 60 cases, of whom 54 were assigned to either tolvaptan group (36) or placebo (18). Overall 36 cases completed the trial (24 from tolvaptan group and 12 cases from placebo group). Estimated GFR (glomerular filtration rate) calculated and stages were noted. TKV and total cyst volume measured by ultrasonography at days 0, 30, 90, and 180 along with other vitals. The total number of patients enrolled was randomly divided into two broad groups by concealed envelop technique: Intervention group (with tolvaptan) and placebo or control group. The intervention group was given tolvaptan along with standard conventional management for ADPKD as per relevant stages. The placebo group was given placebo tablets with same size and color (multivitamin tablet) along with standard conventional management for ADPKD as per relevant stages. The periodic estimation of cyst volume, kidney volume, serum creatinine level, and estimated glomerular filtration rate recorded and analyzed with ANOVA method with confidence interval 95%. Results: Analysis of the data showed fewer ADPKD-related events per cases of follow-up with tolvaptan than with placebo. These results were confirmed by the analysis of the 1st time and after 6 months of study. Our data suggest that increase of TKV and total cyst volume was less in tolvaptan group as compared to placebo group. Overall, treatment effect on the growth of TKV was 0.219% per month with a P<0.0001. Conclusions: The administration of tolvaptan for 6 months was associated with slowed kidney growth and functional decline and with a reduced frequency of ADPKD-related complications among patients with a relatively preserved GFR.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.